Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

Faster-acting insulin aspart (faster aspart) is insulin aspart (IAsp) in a new formulation with additional excipients (L-arginine and niacinamide).

In adults, faster aspart provides faster onset and greater early exposure and action vs IAsp.

Who Took Part

According to the abstract, 12 children were involved.

PubMed indexes the participants as children, teenagers and young adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

The children were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Neither the children nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the children took both Insulin Aspart and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Age Factors, Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents and Insulin Aspart.

The authors tagged it with the keywords adolescents, children and type 1 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 12 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Pediatric diabetes), a journal based in China.

More context: the Insulin Aspart compound page.